In the conducted experiment, it was observed that ADAM17 counteracted the regulatory effects of MALAT1 deletion on oxaliplatin sensitivity in oxaliplatin‐resistant CRC cells.15 This evidence concerns the gene ADAM17 and colorectal carcinoma.